171 related articles for article (PubMed ID: 32691404)
1. Response assessment of somatostatin receptor targeted radioligand therapies for progressive intracranial meningioma.
Müther M; Roll W; Brokinkel B; Zinnhardt B; Sporns PB; Seifert R; Schäfers M; Weckesser M; Stegger L; Stummer W; Rahbar K
Nuklearmedizin; 2020 Sep; 59(5):348-355. PubMed ID: 32691404
[TBL] [Abstract][Full Text] [Related]
2. Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy.
Boursier C; Zaragori T; Bros M; Bordonne M; Melki S; Taillandier L; Blonski M; Roch V; Marie PY; Karcher G; Imbert L; Verger A
Eur Radiol; 2023 Oct; 33(10):7089-7098. PubMed ID: 37148355
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.
Seystahl K; Stoecklein V; Schüller U; Rushing E; Nicolas G; Schäfer N; Ilhan H; Pangalu A; Weller M; Tonn JC; Sommerauer M; Albert NL
Neuro Oncol; 2016 Nov; 18(11):1538-1547. PubMed ID: 27106404
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma.
Kurz SC; Zan E; Cordova C; Troxel AB; Barbaro M; Silverman JS; Snuderl M; Zagzag D; Kondziolka D; Golfinos JG; Chi AS; Sulman EP
Clin Cancer Res; 2024 Feb; 30(4):680-686. PubMed ID: 38048045
[TBL] [Abstract][Full Text] [Related]
5. PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma.
Hänscheid H; Sweeney RA; Flentje M; Buck AK; Löhr M; Samnick S; Kreissl M; Verburg FA
Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1284-8. PubMed ID: 22526964
[TBL] [Abstract][Full Text] [Related]
6. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of hitherto unknown brain meningioma detected on
Parghane RV; Talole S; Basu S
World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of peptide receptor radionuclide therapy with [
Minczeles NS; Bos EM; de Leeuw RC; Kros JM; Konijnenberg MW; Bromberg JEC; de Herder WW; Dirven CMF; Hofland J; Brabander T
Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1195-1204. PubMed ID: 36454268
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE.
Graf J; Pape UF; Jann H; Denecke T; Arsenic R; Brenner W; Pavel M; Prasad V
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):881-894. PubMed ID: 31414209
[TBL] [Abstract][Full Text] [Related]
10. Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma.
Kreissl MC; Hänscheid H; Löhr M; Verburg FA; Schiller M; Lassmann M; Reiners C; Samnick SS; Buck AK; Flentje M; Sweeney RA
Radiat Oncol; 2012 Jun; 7():99. PubMed ID: 22720902
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of
Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S
Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622
[TBL] [Abstract][Full Text] [Related]
12.
Parghane RV; Talole S; Basu S
Ann Nucl Med; 2021 Jan; 35(1):92-101. PubMed ID: 33135123
[TBL] [Abstract][Full Text] [Related]
13. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Parghane RV; Talole S; Prabhash K; Basu S
Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
[TBL] [Abstract][Full Text] [Related]
14. Feasibility and Therapeutic Potential of Combined Peptide Receptor Radionuclide Therapy With Intensive Chemotherapy for Pediatric Patients With Relapsed or Refractory Metastatic Neuroblastoma.
Fathpour G; Jafari E; Hashemi A; Dadgar H; Shahriari M; Zareifar S; Jenabzade AR; Vali R; Ahmadzadehfar H; Assadi M
Clin Nucl Med; 2021 Jul; 46(7):540-548. PubMed ID: 33782280
[TBL] [Abstract][Full Text] [Related]
15. Will
Braat AJAT; Snijders TJ; Seute T; Vonken EPA
Cardiovasc Intervent Radiol; 2019 Nov; 42(11):1649-1652. PubMed ID: 31187231
[TBL] [Abstract][Full Text] [Related]
16. Feasibility and therapeutic potential of the 68Ga/177Lu-DOTATATE theranostic pair in patients with metastatic medullary thyroid carcinoma.
Dadgar H; Jafari E; Ahmadzadehfar H; Rekabpour SJ; Ravanbod MR; Kalantarhormozi M; Nabipour I; Assadi M
Ann Endocrinol (Paris); 2023 Feb; 84(1):45-51. PubMed ID: 36126757
[TBL] [Abstract][Full Text] [Related]
17. Salvage PRRT with
Rudisile S; Gosewisch A; Wenter V; Unterrainer M; Böning G; Gildehaus FJ; Fendler WP; Auernhammer CJ; Spitzweg C; Bartenstein P; Todica A; Ilhan H
BMC Cancer; 2019 Aug; 19(1):788. PubMed ID: 31395036
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin Receptor-Targeted Radioligand Therapy in Head and Neck Paraganglioma.
Roll W; Müther M; Sporns PB; Zinnhardt B; Suero Molina E; Seifert R; Schäfers M; Weckesser M; Stegger L; Beule AG; Stummer W; Rahbar K
World Neurosurg; 2020 Nov; 143():e391-e399. PubMed ID: 32745642
[TBL] [Abstract][Full Text] [Related]
19.
Kowalski ES; Khairnar R; Gryaznov AA; Kesari V; Koroulakis A; Raghavan P; Chen W; Woodworth G; Mishra M
Radiat Oncol; 2021 Aug; 16(1):151. PubMed ID: 34399805
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
